ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
2차 항체 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 18억 1,000만 달러로 평가되었고, 2025년에는 19억 9,000만 달러에 달할 것으로 추정되며, CAGR 10.0%로 성장이 전망되고 있습니다. 지난 수년간의 성장은 단백질 분석에서 웨스턴 블로팅의 채용 증가, 병리학에서 면역조직화학 활용 확대, 진단 및 연구 분야에서 효소 면역측정법의 이용 증가, 면역학 조사에 있어서 유동세포 계측법의 보급 확대, 생명과학 연구에 대한 정부 및 자선 단체로부터의 자금 원조 증가에 기인한 것으로 보입니다.
2차 항체 시장 규모는 향후 수년간 급속한 성장이 예상되고 있습니다. 2029년에는 28억 8,000만 달러에 달할 것으로 예측되며, CAGR 9.6%로 성장이 전망되고 있습니다. 예측 기간에 있어서의 성장요인으로는 바이오의약품 및 바이오테크놀러지 연구 파이프라인 확대, 암 및 자가면역 질환의 유병률 상승, 임상 진단 검사량 증가, 정부 및 민간 연구 자금 증가, 학술 연구 기관 및 연구소 수의 확대 등을 들 수 있습니다. 예측 기간 동안 예상되는 주요 동향으로는 재조합 항체 생산 플랫폼의 진보, 형광 색소 및 효소의 부위 특이적 결합 화학에서 혁신, 비특이적 결합을 최소화하는 고교차 흡착 제제의 개발, 다중 형광 이미징 및 스펙트럼 플로우 사이토메트리 확대, 심부 조직 이미징을 위한 근적외 형광 색소의 채용 확대 등을 들 수 있습니다.
향후 수년간 만성 질환 유병률 상승이 2차 항체 시장의 성장을 견인할 것으로 예측됩니다. 만성 질환은 일반적으로 점진적으로 진행되며 지속적인 의료 관리가 필요한 장기간의 건강 상태를 의미합니다. 이러한 질병 증가는 장기간의 불활성이나 저운동량과 같은 앉기 쉬운 생활 양식에 기인하는 부분이 있어 심장병 및 당뇨병 등의 상태를 조장하고 있습니다. 2차 항체는 바이오마커의 정밀한 검출을 가능하게 함으로써 만성 질환의 관리에 중요한 역할을 하며, 진단 검정 및 질환 진행의 추적에 필수적입니다. 이 항체는 분석의 감도 및 특이성을 향상시키고 적시에 정확한 치료 결정을 촉진합니다. 예를 들어, 2024년 6월에 영국 국민보건서비스(NHS)가 발표한 데이터에 의하면, 2023년 영국에서 비당뇨병성 고혈당 또는 전당뇨병으로 진단된 환자수는 361만 5,330명에 달했으며, 2022년에 비해 18% 증가를 나타냈습니다. 이 결과, 만성 질환 증가 경향이 2차 항체에 대한 수요를 뒷받침하고 있습니다.
2차 항체 시장의 기업은 실험의 재현성 향상, 특이성의 강화, 로트간의 변동 저감을 목적으로 재조합 단일클론항체 등의 혁신적인 제품 개발에 주력하고 있습니다. 재조합 단일클론항체는 유전적으로 정의된 서열을 사용하는 제어된 세포주 시스템에서 생산되므로 높은 일관성 및 지속적인 공급을 보장합니다. 예를 들어, 2023년 10월에는 고품질 항체, 단백질 및 ELISA 키트의 미국 제조업체인 Proteintech Group Inc.가 Multi-rAb 재조합 2차 항체를 출시했습니다. 이러한 항체는 변동이 일어날 수 있는 동물 유래 항체와 달리 제어된 재조합 기술을 사용하여 생성되므로 보다 일관성과 재현성이 우수한 성능을 제공합니다. 면역측정법에서 보다 강력하고 깨끗한 신호 검출을 실현하여 연구자가 저발현 타겟을 보다 선명하게 시각화할 수 있게 합니다. 이 혁신은 특히 면역형광법 및 웨스턴 블로팅과 같은 기술에서 실험의 정확성과 재현성을 향상시켜 보다 신뢰할 수 있는 과학적 결과를 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 2차 항체 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 2차 항체 시장 : 성장률 분석
세계의 2차 항체 시장 실적 : 규모 및 성장(2019-2024년)
세계의 2차 항체 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 2차 항체 시장 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 2차 항체 시장 : 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
모노클로날
폴리클로날
기타 제품 유형
세계의 2차 항체 시장 : 숙주 종별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
염소
토끼
당나귀
마우스
기타 숙주 종
세계의 2차 항체 시장 : 결합 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
효소 표지
형광 색소 표지
비결합형
기타 컨쥬게이트 유형
세계의 2차 항체 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
웨스턴 블로팅
면역조직화학
효소 면역 측정법(ELISA)
플로우 사이토메트리
기타 용도
세계의 2차 항체 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제약 및 생명 공학 기업
학술연구기관
병원 및 진단센터
수탁연구기관(CRO)
세계의 2차 항체 시장 : 모노클로날 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
재조합 모노클로날 2차 항체
하이브리도마 유래 모노클로날 2차 항체
종 특이적 모노클로날 2차 항체
아이소유형 특이적 모노클로날 2차 항체
경쇄 특이적 모노클로날 2차 항체
세계의 2차 항체 시장 : 폴리클로날 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
친화성 정제 폴리클로날 2차 항체
교차 흡착 폴리클로날 2차 항체
고도 교차 흡착 폴리클로날 2차 항체
종 특이적 폴리클로날 2차 항체
아이소유형 특이적 폴리클로날 2차 항체
세계의 2차 항체 시장 : 기타 제품 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단편 항원 결합 2차 항체
단편 결정화 특이적 2차 항체
단일 도메인 항체 2차 항체
나노바디 베이스 2차 항체
프리 흡착 2차 항체
제7장 지역별 및 국가별 분석
세계의 2차 항체 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 2차 항체 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
2차 항체 시장 : 경쟁 구도
2차 항체 시장 : 기업 프로파일
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck KGaA : 개요, 제품 및 서비스, 전략 및 재무 분석
Agilent Technologies Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bio-Techne Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
Miltenyi Biotec GmbH : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
GenScript Biotech Corporation
Promega Corporation
Sino Biological Inc.
Cell Signaling Technology Inc.
Fortis Life Sciences
OriGene Technologies Inc.
Becton Dickinson and Company
GeneTex Inc.
Proteintech Group Inc.
Santa Cruz Biotechnology Inc.
Creative Diagnostics Inc.
Jackson ImmunoResearch Laboratories Inc.
SouthernBiotech LLC
MyBioSource Inc.
Biotium Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
2차 항체 시장(2009년) : 새로운 기회를 제공하는 국가
2차 항체 시장(2009년) : 새로운 기회를 제공하는 부문
2차 항체 시장(2009년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Secondary antibodies are antibodies that specifically bind to the constant regions of primary antibodies in a species- and isotype-specific manner and are often conjugated to reporter molecules for detection. They convert primary antibody binding into a visible, fluorescent, or enzymatic signal, enabling the detection, visualization, or quantification of target antigens.
The primary product types of secondary antibodies include monoclonal, polyclonal, and others. Monoclonal secondary antibodies are produced from a single cloned immune cell and recognize only one specific epitope on an antigen. These antibodies are generated using host species such as goat, rabbit, donkey, mouse, and others, and are available in multiple conjugate formats, including enzyme-conjugated, fluorophore-conjugated, unconjugated, and more. They are used in applications such as western blotting, immunohistochemistry, enzyme-linked immunosorbent assays, flow cytometry, and others. End users include pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers, and contract research organizations (CROs).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The secondary antibodies market research report is one of a series of new reports from The Business Research Company that provides secondary antibodies market statistics, including secondary antibodies industry global market size, regional shares, competitors with a secondary antibodies market share, detailed secondary antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the secondary antibodies industry. This secondary antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The secondary antibodies market size has grown rapidly in recent years. It will grow from $1.81 billion in 2024 to $1.99 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. Growth in the historic period can be attributed to the increasing adoption of western blotting for protein analysis, greater use of immunohistochemistry in pathology, rising utilization of enzyme-linked immunosorbent assays in diagnostics and research, expanding use of flow cytometry in immunology studies, and increased government and philanthropic funding for life science research.
The secondary antibodies market size is expected to see rapid growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. Growth in the forecast period can be attributed to expanding biopharmaceutical and biotechnology research pipelines, the rising prevalence of cancer and autoimmune diseases, increasing clinical diagnostic testing volumes, growing government and private research funding, and the expanding number of academic research institutes and laboratories. Major trends expected in the forecast period include advances in recombinant antibody production platforms, innovations in site-specific conjugation chemistries for fluorophores and enzymes, development of highly cross-adsorbed formulations to minimize nonspecific binding, expansion of multiplexed fluorescence imaging and spectral flow cytometry, and greater adoption of near-infrared fluorophores for deep-tissue imaging.
The rising prevalence of chronic diseases is expected to drive the growth of the secondary antibodies market in the coming years. Chronic diseases are long-lasting health conditions that typically develop gradually and require ongoing medical care. The increasing prevalence of these diseases is partly attributed to sedentary lifestyles, where prolonged periods of inactivity and low physical activity contribute to conditions like heart disease and diabetes. Secondary antibodies play a crucial role in managing chronic diseases by enabling the precise detection of biomarkers, making them essential for diagnostic assays and tracking disease progression. These antibodies enhance the sensitivity and specificity of assays, facilitating timely and accurate treatment decisions. For instance, in June 2024, the National Health Service (NHS) reported that 3,615,330 individuals in the UK were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase compared to 2022. As a result, the growing prevalence of chronic diseases is fueling the demand for secondary antibodies.
Companies in the secondary antibodies market are focusing on developing innovative products, such as recombinant monoclonal antibodies, to improve experimental reproducibility, enhance specificity, and reduce variability between lots. Recombinant monoclonal antibodies are produced in controlled cell line systems using genetically defined sequences, ensuring high consistency and a continuous supply. For example, in October 2023, Proteintech Group Inc., a US-based manufacturer of high-quality antibodies, proteins, and ELISA kits, launched its Multi-rAb Recombinant Secondary Antibodies. These antibodies offer more consistent and reproducible performance since they are generated using controlled recombinant technology, as opposed to animal-derived antibodies, which can exhibit variability. They provide stronger and cleaner signal detection in immunoassays, allowing researchers to visualize low-abundance targets with greater clarity. This innovation improves the accuracy and reproducibility of experiments, particularly in techniques like immunofluorescence and western blotting, leading to more reliable scientific results.
In September 2024, Leinco Technologies Inc., a US-based biotechnology company, acquired QED Bioscience Inc. for an undisclosed amount. This acquisition allows Leinco Technologies to expand its antibody capabilities and enhance its product portfolio, serving research and diagnostic markets globally. QED Bioscience is a US-based company specializing in the development of secondary antibodies and related immunoassay reagents.
Major companies operating in the secondary antibodies market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Bio-Techne Corporation, Miltenyi Biotec GmbH, GenScript Biotech Corporation, Promega Corporation, Sino Biological Inc., Cell Signaling Technology Inc., Fortis Life Sciences, OriGene Technologies Inc., Becton Dickinson and Company, GeneTex Inc., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Creative Diagnostics Inc., Jackson ImmunoResearch Laboratories Inc., SouthernBiotech LLC, MyBioSource Inc., Biotium Inc.
North America was the largest region in the secondary antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in secondary antibodies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the secondary antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The secondary antibodies consists of sales of labeled antibodies, unlabeled antibodies, fragment antibodies, conjugated antibodies, fluorescently-labeled antibodies, and biotinylated antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Secondary Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on secondary antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for secondary antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The secondary antibodies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Monoclonal; Polyclonal; Other Product Types
2) By Host Species: Goat; Rabbit; Donkey; Mouse; Other Host Species
3) By Conjugate Type: Enzyme-Conjugated; Fluorophore-Conjugated; Unconjugated; Other Conjugate Types
4) By Application: Western Blotting; Immunohistochemistry; Enzyme-Linked Immunosorbent Assay (ELISA); Flow Cytometry; Other Applications
5) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Hospitals And Diagnostic Centers; Contract Research Organizations (CROs)
Subsegments:
1) By Monoclonal: Recombinant Monoclonal Secondary Antibody; Hybridoma Derived Monoclonal Secondary Antibody; Species Specific Monoclonal Secondary Antibody; Isotype Specific Monoclonal Secondary Antibody; Light Chain Specific Monoclonal Secondary Antibody
2) By Polyclonal: Affinity Purified Polyclonal Secondary Antibody; Cross Adsorbed Polyclonal Secondary Antibody; Highly Cross Adsorbed Polyclonal Secondary Antibody; Species Specific Polyclonal Secondary Antibody; Isotype Specific Polyclonal Secondary Antibody
3) By Other Product Types: Fragment Antigen Binding Secondary Antibody; Fragment Crystallizable Specific Secondary Antibody; Single Domain Antibody Secondary Reagent; Nanobody Based Secondary Reagent; Pre Adsorbed Secondary Antibody
Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Agilent Technologies Inc.; Bio-Techne Corporation; Miltenyi Biotec GmbH; GenScript Biotech Corporation; Promega Corporation; Sino Biological Inc.; Cell Signaling Technology Inc.; Fortis Life Sciences; OriGene Technologies Inc.; Becton Dickinson and Company; GeneTex Inc.; Proteintech Group Inc.; Santa Cruz Biotechnology Inc.; Creative Diagnostics Inc.; Jackson ImmunoResearch Laboratories Inc.; SouthernBiotech LLC; MyBioSource Inc.; Biotium Inc.
Countries:
Table of Contents
1. Executive Summary
2. Secondary Antibodies Market Characteristics
3. Secondary Antibodies Market Trends And Strategies
4. Secondary Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Secondary Antibodies Growth Analysis And Strategic Analysis Framework
5.1. Global Secondary Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Secondary Antibodies Market Growth Rate Analysis
5.4. Global Secondary Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Secondary Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Secondary Antibodies Total Addressable Market (TAM)
6. Secondary Antibodies Market Segmentation
6.1. Global Secondary Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal
Polyclonal
Other Product Types
6.2. Global Secondary Antibodies Market, Segmentation By Host Species, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Goat
Rabbit
Donkey
Mouse
Other Host Species
6.3. Global Secondary Antibodies Market, Segmentation By Conjugate Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme-Conjugated
Fluorophore-Conjugated
Unconjugated
Other Conjugate Types
6.4. Global Secondary Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Western Blotting
Immunohistochemistry
Enzyme-Linked Immunosorbent Assay (ELISA)
Flow Cytometry
Other Applications
6.5. Global Secondary Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical And Biotechnology Companies
Academic And Research Institutes
Hospitals And Diagnostic Centers
Contract Research Organizations (CROs)
6.6. Global Secondary Antibodies Market, Sub-Segmentation Of Monoclonal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Monoclonal Secondary Antibody
Hybridoma Derived Monoclonal Secondary Antibody
Species Specific Monoclonal Secondary Antibody
Isotype Specific Monoclonal Secondary Antibody
Light Chain Specific Monoclonal Secondary Antibody
6.7. Global Secondary Antibodies Market, Sub-Segmentation Of Polyclonal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.8. Global Secondary Antibodies Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fragment Antigen Binding Secondary Antibody
Fragment Crystallizable Specific Secondary Antibody
Single Domain Antibody Secondary Reagent
Nanobody Based Secondary Reagent
Pre Adsorbed Secondary Antibody
7. Secondary Antibodies Market Regional And Country Analysis
7.1. Global Secondary Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Secondary Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
